Sarah Wall, MD, talks about how it’s important to consider patient age when treating older patients with cancer because it will impact so many of them and blood cancers act differently and can be more aggressive in older adults.
With the population of older adults growing, it is becoming more important for providers to put attention on older adults, who are more likely to be diagnosed with cancer and in whom blood-based cancers function differently and more aggressively, explains Sarah Wall, MD, assistant professor in the Division of Hematology at The Ohio State University.
Transcript
Why is it important to study the relationship between age and hematological diseases and hematological cancers?
It's a really important question because it affects so many people, and I think that's the easy answer. In the US, the average age of the population is continuing to rise. The estimates are that by 2030, more than two-thirds of the population will be above the age of 60. Along with that, we would expect about 70% of those older adults to be diagnosed with a cancer because cancers are often diagnosed in older people related to changes that occur with age.
For blood cancers, in particular, it's also an important question because a lot of blood cancers behave differently in older adults. In acute myeloid leukemia, for example, there has been research looking at the differences in disease genetic markers, between patients younger than 60 and older than 60. Patients who are older than 60 with the same mutations as the younger group will behave differently and often will have more aggressive disease features. These are important things to take into consideration when you're treating these patients, that even though they may look the same by mutational status, the age may make a difference.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More